Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMCR Immunocore Holdings plc
- Stocks
- Healthcare
- NASDAQ: IMCR
Price (delayed)
$28.4
Market cap
$1.43B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.43
Enterprise value
$1.38B
immunocore is a privately owned biotechnology company developing innovative biological therapeutics for the treatment of a range of serious diseases. its world-leading t cell receptor technology exploits the power of
Highlights
The EPS has surged by 65% year-on-year and by 58% since the previous quarter
IMCR's net income has soared by 64% YoY and by 58% QoQ
Key stats
What are the main financial stats of IMCR
Market
Valuations
Earnings
Shares outstanding
50.23M
Market cap
$1.43B
Enterprise value
$1.38B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.76
Price to sales (P/S)
4.26
EV/EBIT
N/A
EV/EBITDA
717.36
EV/Sales
4.15
Revenue
$333.58M
Gross profit
$330.27M
Operating income
-$47.59M
Net income
-$21.63M
EBIT
-$4.14M
EBITDA
$1.93M
Free cash flow
$26.09M
Per share
Balance sheet
Liquidity
EPS
-$0.43
EPS diluted
-$0.43
Free cash flow per share
$0.52
Book value per share
$7.56
Revenue per share
$6.66
TBVPS
$20.52
Total assets
$1.03B
Total liabilities
$649.53M
Debt
$434M
Equity
$378.48M
Working capital
$799.46M
Debt to equity
1.15
Current ratio
6.36
Quick ratio
6.03
Net debt/EBITDA
-22.21
Margins
Efficiency
Dividend
EBITDA margin
0.6%
Gross margin
99%
Net margin
-6.5%
Operating margin
-14.3%
Return on assets
-2.1%
Return on equity
-5.9%
Return on invested capital
-0.5%
Return on capital employed
-0.5%
Return on sales
-1.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMCR stock price
How has the Immunocore Holdings stock price performed over time
Intraday
-4.67%
1 week
-6.76%
1 month
8.73%
1 year
-52.55%
YTD
-3.73%
QTD
-4.28%
Financial performance
How have Immunocore Holdings's revenue and profit performed over time
Revenue
$333.58M
Gross profit
$330.27M
Operating income
-$47.59M
Net income
-$21.63M
Gross margin
99%
Net margin
-6.5%
The net margin has soared by 71% YoY and by 61% from the previous quarter
IMCR's net income has soared by 64% YoY and by 58% QoQ
The operating margin rose by 47% YoY and by 37% QoQ
IMCR's operating income is up by 33% year-on-year and by 32% since the previous quarter
Price vs fundamentals
How does IMCR's price correlate with its fundamentals
Growth
What is Immunocore Holdings's growth rate over time
Valuation
What is Immunocore Holdings stock price valuation
P/E
N/A
P/B
3.76
P/S
4.26
EV/EBIT
N/A
EV/EBITDA
717.36
EV/Sales
4.15
The EPS has surged by 65% year-on-year and by 58% since the previous quarter
IMCR's price to book (P/B) is 42% less than its 5-year quarterly average of 6.5 and 10% less than its last 4 quarters average of 4.2
The equity rose by 5% year-on-year and by 4.9% since the previous quarter
The stock's price to sales (P/S) is 78% less than its 5-year quarterly average of 19.7 and 16% less than its last 4 quarters average of 5.1
The revenue is up by 26% year-on-year and by 8% since the previous quarter
Efficiency
How efficient is Immunocore Holdings business performance
The ROIC has soared by 98% YoY and by 90% QoQ
The return on sales has surged by 95% year-on-year and by 89% since the previous quarter
The return on assets has surged by 76% year-on-year and by 58% since the previous quarter
The ROE has soared by 65% year-on-year and by 58% since the previous quarter
Dividends
What is IMCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMCR.
Financial health
How did Immunocore Holdings financials performed over time
The total assets is 58% greater than the total liabilities
The current ratio rose by 45% QoQ and by 7% YoY
Immunocore Holdings's quick ratio has increased by 45% from the previous quarter and by 5% YoY
The debt is 15% more than the equity
The debt to equity is down by 12% year-on-year and by 4.2% since the previous quarter
The debt has contracted by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.